VRTX Stock Summary and Trading Ideas (Vertex Pharmaceuticals | NASDAQ:VRTX)

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Vertex Pharmaceuticals trades on the NASDAQ stock market under the symbol VRTX.

As of April 2, 2026, VRTX stock price declined to $438.71 with 1,085,168 million shares trading.

VRTX has a beta of 0.38, meaning it tends to be less sensitive to market movements. VRTX has a correlation of 0.03 to the broad based SPY ETF.

VRTX has a market cap of $111.45 billion. This is considered a Large Cap stock.

Last quarter Vertex Pharmaceuticals reported $3 billion in Revenue and $5.03 earnings per share. This beat revenue expectation by $17 million and exceeded earnings estimates by $.18.

In the last 3 years, VRTX traded as high as $519.88 and as low as $313.47.

The top ETF exchange traded funds that VRTX belongs to (by Net Assets): VTI, VOO, QQQ, IVV, VUG.

VRTX has underperformed the market in the last year with a price return of -9.3% while the SPY ETF gained +17.5%. However, in the short term, VRTX had mixed performance relative to the market. It has outperformed in the last 3 months, returning -3.0% vs -3.7% return in SPY. But in the last 2 weeks, VRTX shares have been beat by the market, returning -4.2% compared to an SPY return of -0.1%.

VRTX support price is $437.78 and resistance is $456.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRTX shares will trade within this expected range on the day.